ClinicalTrials.gg
CompletedNCT04599855Updated Apr 25, 2025Results posted

A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression

A Phase 4 interventional study of Esketamine 56 mg and Esketamine 84 mg in Depressive Disorder, Treatment-Resistant, sponsored by Janssen Research & Development, LLC. Completed at 54 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-25.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
477
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies testing esketamine in Depressive Disorder, Treatment-Resistant — 4 open to participants now, 4 under way, 2 of them phase 3. Esketamine · Depressive Disorder, Treatment-Resistant.

Enrollment
4th of 18
477 · median 210
Started
2020
the only one that year
Phase 4
4 of 18
1 open now
Registered
11th of 18
by date
Lead sponsor
11 of 18
Janssen Research & Development, LLC

Among the 18 studies testing esketamine in Depressive Disorder, Treatment-Resistant, this one is the 4th largest by enrollment, is the only one that started in 2020, is one of 4 in phase 4, and was the 11th registered.

Depressive Disorder, Treatment-Resistant

448 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 147 are open to participants now.

Browse Depressive Disorder, Treatment-Resistant studies →

Open to participants now

4 of the 18 studies testing esketamine in Depressive Disorder, Treatment-Resistant are open now, in 11 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About esketamine

Esketamine: first FDA approval 2019 (SPRAVATO), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 114 Depressive Disorder, Treatment-Resistant studies recruiting now, 26 (23%) set no upper age limit and 76 (67%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing esketamine in Depressive Disorder, Treatment-Resistant, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of each individual dose of esketamine nasal spray, 56 milligram (mg) and 84 mg, compared with placebo nasal spray in improving depressive symptoms in participants with treatment resistant depression (TRD), as assessed by the change from baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) total score from Day 1 (prerandomization) to the end of the 4 week double-blind treatment phase (Day 28).

03

Conditions studied

  • Depressive Disorder, Treatment-Resistant
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must meet the (5th edition) (DSM-5) diagnostic criteria for single-episode MDD or recurrent MDD, without psychotic features, based upon clinical assessment and confirmed by the MINI. Participants 65 years of age or older must have had the first onset of depression prior to 55 years of age
  • Participant must have had nonresponse (\<=25% improvement) to >=2 oral antidepressant treatments in the current episode of depression, assessed using the MGH-ATRQ, and confirmed by documented records (example, medical/pharmacy/prescription records or a letter from a treating physician)
  • Participant must have an Inventory of Depressive Symptomatology-Clinician rated, 30-item (IDS-C30) total score of >=34
  • The participant's current major depressive episode, depression symptom severity, and antidepressant treatment response in the current depressive episode, must be confirmed by the State vs. Trait, Assessibility, Face Validity, Ecological Validity, Rule of Three P's (SAFER) Interview
  • Participant must be medically stable on the basis of physical examination, medical history, vital signs (including blood pressure), and 12-lead (ECG) performed in the screening phase. If there are any abnormalities that are not specified in the inclusion and exclusion criteria, the determination of their clinical significance must be determined by the investigator and recorded in the participant's source documents and initiated by the investigator
  • Participant must be medically stable on the basis of clinical laboratory tests performed in the screening phase. If the results of the serum chemistry panel, hematology, or urinalysis are outside the normal reference ranges, the participant may be included only if the investigator judges the abnormalities or deviations from normal to be not or to be appropriate and reasonable for the population under study. This determination must be recorded in the participant's source documents and initialed by the investigator: (a) Participants with a pre-existing history of thyroid disease/disorder who are treated with thyroid hormones must be on a stable dosage for 3 months prior to the start of the screening phase; (b) For any participant (regardless of thyroid history), if the thyroid-stimulating hormone (TSH) value is out of range, a free thyroxine (FT4) will be conducted. If the FT4 value is abnormal and considered to be clinically significant (after discussion with the medical monitor), the participant is not eligible
  • Participant must be comfortable with self-administration of nasal spray medication and be able to follow the nasal spray administration instructions provided

Exclusion criteria

Exclusion Criteria:

  • The participant has used ketamine/esketamine (lifetime)
  • The participant's depressive symptoms have previously demonstrated nonresponse to an adequate course of treatment with electroconvulsive therapy (ECT) in the current major depressive episode, defined as at least 7 treatments with unilateral/bilateral ECT
  • Participant has received vagal nerve stimulation (VNS) or has received deep brain stimulation (DBS) in the current episode of depression
  • Participant has a current or history of seizures (uncomplicated childhood febrile seizures with no sequelae are not exclusionary)
  • Participant has any anatomical or medical condition that, per the investigator's clinical judgment based on assessment, may impede delivery or absorption of nasal spray study drug
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
477 participants (actual)

Study arms

  • Experimental
    Esketamine 56 Milligram (mg)

    Participants will receive nasal spray treatment with esketamine 56 mg twice a week for 4 weeks. Participants may participate in an open-label treatment/observation phase, following completion of the double-blind treatment phase assessments (which includes the Day 28 Montgomery-Asberg Depression Rating Scale \[MADRS\] assessment).

    Drug: Esketamine 56 mg

  • Experimental
    Esketamine 84 mg

    Participants will receive nasal spray treatment with esketamine 84 mg twice a week for 4 weeks. Participants may participate in an open-label treatment/observation phase, following completion of the double-blind treatment phase assessments (which includes the Day 28 MADRS assessment).

    Drug: Esketamine 84 mg

  • Experimental
    Placebo

    Participants will receive nasal spray treatment with placebo twice a week for 4 weeks. Participants may participate in an open-label treatment/observation phase, following completion of the double-blind treatment phase assessments (which includes the Day 28 MADRS assessment).

    Drug: Placebo

Interventions

  • Esketamine 56 mg will be self administered as nasal spray.

    Also known as: JNJ-54135419

  • Esketamine 84 mg will be self administered as nasal spray.

    Also known as: JNJ-54135419

  • DrugPlacebo

    Matching placebo will be self administered as nasal spray.

06

What researchers measure

Primary outcomes

  1. Double-blind Treatment Phase: Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Day 1 (Pre-randomization) to Day 28

    The MADRS was a clinician-rated scale designed to measure depression severity and detect changes due to antidepressant treatment. The scale consisted of 10 items, each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition. The MADRS evaluated apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, inability to feel (interest level), pessimistic thoughts, and suicidal thoughts. Negative change in MADRS total score indicated improvement.

    Time frame: Day 1 (pre-randomization) to Day 28 (end of DB treatment phase)

Secondary outcomes

  1. Double-blind Treatment Phase: Change in MADRS Total Score From Day 1 (Pre-randomization) to Day 2 (24 Hours Post First Dose on Day 1)

    The MADRS was a clinician-rated scale designed to measure depression severity and detect changes due to antidepressant treatment. The scale consisted of 10 items, each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition. The MADRS evaluated apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, inability to feel (interest level), pessimistic thoughts, and suicidal thoughts. Negative change in MADRS total score indicated improvement.

    Time frame: Day 1 (pre-randomization) to Day 2 of DB treatment phase (24 hours post first dose on Day 1)

07

Results

Posted Mar 4, 2025

Participant flow

Adult participants with recurrent or single (duration greater than or equal to \[\>=\] 2 years) episode major depressive disorder (DSM-5 criteria) without psychotic features who experienced inadequate response (less than or equal to \[\<=\] 25 percent \[%\] improvement) to \>=2 oral antidepressants during the current depressive episode were randomized in the study.

Double Blind Period (Day 1 to Day 28)
Participant flow — Double Blind Period (Day 1 to Day 28)
MilestonePlaceboEsketamine 56 mgEsketamine 84 mg
Started250106121
Treated250105121
Completed238101107
Not completed12514
Withdrew: Withdrawal by subject525
Withdrew: Adverse event215
Withdrew: Lack of efficacy202
Withdrew: Protocol violation101
Withdrew: Lost to follow-up010
Withdrew: Pregnancy100
Withdrew: Other101
Withdrew: Randomized but not treated010
Period Title: OL Period (Week 5 to 16)
Participant flow — Period Title: OL Period (Week 5 to 16)
MilestonePlaceboEsketamine 56 mgEsketamine 84 mg
Started23799106
Participants who entered ol treatment phase23799105
Participants who entered ol observation phase001
Completed2048795
Not completed331211
Withdrew: Withdrawal by subject856
Withdrew: Lack of efficacy1032
Withdrew: Adverse event421
Withdrew: Lost to follow-up412
Withdrew: Protocol violation200
Withdrew: Other510

Outcome measures

PrimaryDouble-blind Treatment Phase: Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Day 1 (Pre-randomization) to Day 28

The MADRS was a clinician-rated scale designed to measure depression severity and detect changes due to antidepressant treatment. The scale consisted of 10 items, each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition. The MADRS evaluated apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, inability to feel (interest level), pessimistic thoughts, and suicidal thoughts. Negative change in MADRS total score indicated improvement.

Time frame:
Day 1 (pre-randomization) to Day 28 (end of DB treatment phase)
Reported as:
Mean · Score on a scale
Double-blind Treatment Phase: Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Day 1 (Pre-randomization) to Day 28
Score on a scaleDB: PlaceboDB: Esketamine 56 mgDB: Esketamine 84 mg
Double-blind Treatment Phase: Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Day 1 (Pre-randomization) to Day 28-7.0 ± 10.07-12.7 ± 11.82-13.9 ± 11.89
Statistical analysis
  • DB: Placebo vs DB: Esketamine 56 mg · Mixed model for repeated measures · p = <0.001 · Least square (ls) means difference: -5.1 · 95% CI -7.91 to -2.33
  • DB: Placebo vs DB: Esketamine 84 mg · Mixed model for repeated measures · p = <0.001 · Ls means difference: -6.8 · 95% CI -9.48 to -4.07
SecondaryDouble-blind Treatment Phase: Change in MADRS Total Score From Day 1 (Pre-randomization) to Day 2 (24 Hours Post First Dose on Day 1)

The MADRS was a clinician-rated scale designed to measure depression severity and detect changes due to antidepressant treatment. The scale consisted of 10 items, each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition. The MADRS evaluated apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, inability to feel (interest level), pessimistic thoughts, and suicidal thoughts. Negative change in MADRS total score indicated improvement.

Time frame:
Day 1 (pre-randomization) to Day 2 of DB treatment phase (24 hours post first dose on Day 1)
Reported as:
Mean · Score on a scale
Double-blind Treatment Phase: Change in MADRS Total Score From Day 1 (Pre-randomization) to Day 2 (24 Hours Post First Dose on Day 1)
Score on a scaleDB: PlaceboDB: Esketamine 56 mgDB: Esketamine 84 mg
Double-blind Treatment Phase: Change in MADRS Total Score From Day 1 (Pre-randomization) to Day 2 (24 Hours Post First Dose on Day 1)-9.7 ± 10.27-13.9 ± 10.15-13.0 ± 9.68
Statistical analysis
  • DB: Placebo vs DB: Esketamine 56 mg · Mixed model for repeated measures · p = =0.004 · Ls means difference: -3.8 · 95% CI -6.29 to -1.22
  • DB: Placebo vs DB: Esketamine 84 mg · Mixed model for repeated measures · p = =0.006 · Ls means difference: -3.4 · 95% CI -5.89 to -1.00

Adverse events

Collected over Double-blind (DB) phase: From Day 1 (post-dose) to Day 28; Open-label (OL) phase: From Week 5 to Week 16; Follow-up (FU) phase: Up to 1 week after last dose of study drug in DB phase (Week 5) or OL treatment phase (Week 17). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DB: Placebo0/250 (0%)3/250 (1.2%)73/250 (29.2%)
DB: Esketamine 56 mg0/106 (0%)1/105 (1%)69/105 (65.7%)
DB: Esketamine 84 mg0/121 (0%)2/121 (1.7%)80/121 (66.1%)
OL Treatment: Placebo to Esketamine0/237 (0%)6/237 (2.5%)147/237 (62%)
OL Treatment: Esketamine 56 mg to Esketamine0/99 (0%)3/99 (3%)49/99 (49.5%)
OL Treatment: Esketamine 84 mg to Esketamine0/105 (0%)0/105 (0%)44/105 (41.9%)
OL Observation Period0/1 (0%)0/1 (0%)0/1 (0%)
Follow up: All Participants0/477 (0%)1/476 (0.2%)8/476 (1.7%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventDB: PlaceboDB: Esketamine 56 mgDB: Esketamine 84 mgOL Treatment: Placebo to EsketamineOL Treatment: Esketamine 56 mg to EsketamineOL Treatment: Esketamine 84 mg to EsketamineOL Observation PeriodFollow up: All Participants
Abdominal Hernia ObstructiveGastrointestinal disorders0/2500/1050/1210/2371/990/1050/10/476
PeritonitisInfections and infestations0/2500/1050/1210/2371/990/1050/10/476
Endometrial CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2500/1050/1210/2371/990/1050/10/476
Ankle FractureInjury, poisoning and procedural complications0/2501/1050/1210/2370/990/1050/10/476
Breast CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2500/1050/1212/2370/990/1050/10/476
Ophthalmic MigraineNervous system disorders0/2500/1051/1210/2370/990/1050/10/476
Suicide AttemptPsychiatric disorders0/2500/1051/1210/2370/990/1050/10/476
ConstipationGastrointestinal disorders0/2500/1050/1211/2370/990/1050/10/476
VomitingGastrointestinal disorders0/2500/1050/1211/2370/990/1050/10/476
Colon CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2500/1050/1211/2370/990/1050/10/476
Most frequent other events
Showing 10 of 15
Most frequent other events
EventDB: PlaceboDB: Esketamine 56 mgDB: Esketamine 84 mgOL Treatment: Placebo to EsketamineOL Treatment: Esketamine 56 mg to EsketamineOL Treatment: Esketamine 84 mg to EsketamineOL Observation PeriodFollow up: All Participants
NauseaGastrointestinal disorders21/25024/10532/12169/23718/9915/1050/10/476
DissociationPsychiatric disorders7/25023/10532/12142/23712/9915/1050/10/476
DizzinessNervous system disorders18/25022/10527/12145/2378/9910/1050/11/476
HeadacheNervous system disorders22/25019/10524/12136/23713/9911/1050/12/476
VomitingGastrointestinal disorders1/2505/10510/12127/2376/992/1050/11/476
AnxietyPsychiatric disorders3/2505/10510/12114/2373/994/1050/10/476
FatigueGeneral disorders11/2508/1057/12118/2376/995/1050/10/476
Feeling DrunkGeneral disorders2/2508/1058/12113/2376/996/1050/10/476
DiarrhoeaGastrointestinal disorders6/2503/1051/12116/2375/993/1050/11/476
HypoaesthesiaNervous system disorders1/2502/1055/12115/2372/994/1050/10/476

Baseline characteristics

Safety analysis set included all randomized participants (participants who met and did not meet nonresponse criteria) who received at least 1 dose of DB study intervention.

Age, Categorical
Age, Categorical(Participants)PlaceboEsketamine 56 mgEsketamine 84 mgTotal
<=18 years0000
Between 18 and 65 years22995107431
>=65 years21101445
Age, Continuous
Age, Continuous(Years)PlaceboEsketamine 56 mgEsketamine 84 mgTotal
Mean45.4 ± 13.7245.1 ± 13.9245.1 ± 14.7545.3 ± 14.01
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboEsketamine 56 mgEsketamine 84 mgTotal
Female1476077284
Male1034544192
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboEsketamine 56 mgEsketamine 84 mgTotal
Hispanic or Latino259842
Not Hispanic or Latino22195112428
Unknown or Not Reported4116
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboEsketamine 56 mgEsketamine 84 mgTotal
American Indian or Alaska Native0101
Asian63514
Native Hawaiian or Other Pacific Islander0112
Black or African American1771135
White21791102410
More than one race6129
Unknown or Not Reported4105
Region of Enrollment
Region of Enrollment(Participants)PlaceboEsketamine 56 mgEsketamine 84 mgTotal
United States250105121476
08

Study locations

54 sites
  • UAB Department of Psychiatry and Behavioral Neurobiology
    Birmingham, Alabama 35294, United States
  • UAB Huntsville Regional Medical Campus
    Huntsville, Alabama 35801, United States
  • Preferred Research Partners
    Little Rock, Arkansas 72211, United States
  • Behavioral Research Specialists LLC
    Glendale, California 91206, United States
  • CalNeuro Research
    Los Angeles, California 90025, United States
  • Pacific Research Partners
    Oakland, California 94607, United States
  • Anderson Clinical Research
    Redlands, California 92374, United States
  • University of California at San Diego
    San Diego, California 92103-8620, United States
  • Artemis Institute for Clinical Research
    San Diego, California 92103, United States
  • UCSF Nancy Friend Pritzker Psychiatry Building
    San Francisco, California 94143, United States
  • Velocity Clinical Research
    Santa Ana, California 91704, United States
  • CMB Clinical Trials
    Santee, California 92071, United States
  • University of Connecticut Health Center
    Farmington, Connecticut 06032, United States
  • Velocity Clinical Research, Hallandale Beach
    Hallandale Beach, Florida 33009, United States
  • Accel Research Sites
    Lakeland, Florida 33803, United States
  • APG Research LLC
    Orlando, Florida 32803, United States
  • USF, Department of Psychiatry and Behavioral Neurosciences
    Tampa, Florida 33613, United States
  • Neuroscience Research Institute
    West Palm Beach, Florida 33407, United States
  • Atlanta Behavioral Research, LLC
    Atlanta, Georgia 30338, United States
  • Psych Atlanta, P.C.
    Marietta, Georgia 30060, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Chicago Research Center
    Chicago, Illinois 60634, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • Joliet Center for Clinical Research
    Joliet, Illinois 60435, United States
  • Pillar Clinical Research, LLC
    Lincolnwood, Illinois 60712, United States
  • Psychiatric Medicine Associates LLC
    Skokie, Illinois 60076, United States
  • Ascension via Christi Research
    Wichita, Kansas 67214, United States
  • University of Kansas School of Medicine
    Wichita, Kansas 67214, United States
  • Sheppard Pratt Health System
    Baltimore, Maryland 21204, United States
  • CBH Health
    Gaithersburg, Maryland 20877, United States
  • Copley Clinical
    Boston, Massachusetts 02116, United States
  • Adams Clinical
    Watertown, Massachusetts 02472, United States
  • University of Massachusetts Medical School
    Worcester, Massachusetts 01655, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Rochester Center for Behavioral Medicine (RCBM)
    Rochester Hills, Michigan 48307, United States
  • Midwest Research Group - St. Charles Psychiatric Associates
    Saint Charles, Missouri 63304, United States
  • Clinilabs
    New York, New York 10016, United States
  • The Medical Research Network, LLC
    New York, New York 10128, United States
  • Stony Brook University Medical Center
    Stony Brook, New York 11794, United States
  • Ohio State University
    Columbus, Ohio 43210, United States
  • Midwest Clinical Research Center
    Dayton, Ohio 45417, United States
  • Paradigm Research Professionals, LLC
    Oklahoma City, Oklahoma 73118, United States
  • Lehigh Center for Clinical Research
    Allentown, Pennsylvania 18104, United States
  • University of Pennsylvania Medical Center
    Philadelphia, Pennsylvania 19104, United States
  • The Warren Alpert Medical School of Brown University - Butler Hospital
    Providence, Rhode Island 02906, United States
  • BioBehavioral Research of Austin PC
    Austin, Texas 78759, United States
  • Relaro Medical Trials
    Dallas, Texas 75243, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75247, United States
  • Brain Health Consultants and TMS Center
    Houston, Texas 77046, United States
  • The University of Texas Health Science Center at Houston
    Houston, Texas 77054, United States
  • Pillar Clinical Research, LLC
    Richardson, Texas 75080, United States
  • Family Psychiatry of The Woodlands
    The Woodlands, Texas 77381, United States
  • Grayline Research Center
    Wichita Falls, Texas 76309, United States
  • University of Virginia Center for Psychiatric Clinical Research
    Charlottesville, Virginia 22903, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in Jan 2024, 38 months.

Results were first posted in Mar 2025, 1 year 1 month after primary completion.

Of 18 phase 4 interventional studies under Depressive Disorder, Treatment-Resistant, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 59. This study's 38 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2020
First posted
Oct 23, 2020
StartActual
Nov 4, 2020
Primary completionActual
Jan 31, 2024
CompletionActual
Jan 31, 2024
Results first posted
Mar 4, 2025
Last update
Apr 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04599855
Responsible party
Sponsor
First posted
Oct 23, 2020
Start date
Nov 4, 2020
Primary completion
Jan 31, 2024
Completion
Jan 31, 2024
Results posted
Mar 4, 2025
Last update
Apr 25, 2025

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Esketamine

Start the discussion